Abstract:

Although existing anti-tuberculosis treatment regimens have achieved remarkable results in the treatment of patients with drug-susceptible tuberculosis, the problems of drug toxicity and resistant strains are increasingly prominent. As a result, new drugs and treatment strategies are developed to better treat tuberculosis. Host-directed therapy (HDT) uses small molecule compounds to modulate the host’s immune response, thereby to protect tissues and eliminate pathogens. The main purpose of HDT is to enhance the host’s anti-tuberculosis immune function while shorten the duration of traditional antibiotic therapy and improve the treatment effect, which is regarded as a promising method for the treatment of tuberculosis. Tyrosine kinase (PTK) is mainly involved in activating cell signal transduction, to regulate a series of physiological and biochemical processes such as cell growth, proliferation, and death. Tyrosine kinase inhibitor (TKI) is a novel anticancer drug that can target overexpressed cellular pathways in a variety of malignant tumors, and can also exert antitumor activity by inducing autophagy and activating other signaling pathways. It has been found that TKI can also regulate the signal transduction process in macrophages and reduce the intracellular Mycobacterium tuberculosis (MTB) load, which has great therapeutic potential. Therefore, TKI can be used as potential candidates for HDT in the clinical adjuvant treatment of tuberculosis. In this paper, the potential targeted drug research for the treatment of tuberculosis by transferring PTK and signaling were reviewed, aiming to provide a reference for better application of existing drugs and the development of new drugs for the treatment of tuberculosis.

Key words: Tuberculosis, Antitubercular agents, Host-pathogen interactions, Protein-tyrosine kinases